What Delispect does

Delispect (株式会社DELISPECT) is a Tokyo-based, privately held medical technology startup founded in September 2024 by Kaneta Satoshi (CEO, formerly of Fujitsu and NTT Data) and Dr. Ogawa Asao (Chief of Psycho-Oncology at the National Cancer Center East Hospital) to commercialize an AI-based medical device for predicting and managing delirium in elderly hospitalized patients. The company sells two integrated products: a delirium onset prediction model — a proprietary machine learning model trained on more than 100,000 clinical data samples drawn from routine hospital-collected patient data, requiring no invasive sensors or new data collection — and a delirium care navigation application that standardizes delirium prevention care by guiding nurses and caregivers through individualized care plans developed under the supervision of delirium researchers and trained nurses.

The technology is a Japan-only B2B medical device SaaS offering intended to be deployed through direct enterprise sales to hospital management, clinical departments, and IT teams. Pricing is not publicly disclosed and requires direct inquiry; the revenue model is assumed to involve software licensing or subscription to hospitals with related professional services, though no revenue is currently generated. The company is currently operating in a pre-commercialization phase, with its four named clinical research partners (National Cancer Center East Hospital, Juntendo University Hospital, St. Luke's International Hospital, and Kumamoto Red Cross Hospital) functioning as model development and validation collaborators rather than paying customers.

Delispect has positioned itself within the Japanese healthcare policy environment, securing consecutive-year AMED (Japan Agency for Medical Research and Development) selection (FY2022 medical device development and FY2025 digital healthcare acceleration programs), National Cancer Center venture certification (January 2025), INPIT IPAS intellectual property acceleration (June 2025), Tokyo Metropolitan Government's TOKYO SUTEAM program (May 2025), and a seed investment from healthcare-focused BD Fund (August 2025), alongside a planned equity crowdfunding campaign on FUNDINNO. The company operates from Nihonbashi, Chuo-ku, Tokyo, and is certified as a National Cancer Center spin-off venture.

Name

Delispect

Legal name

株式会社DELISPECT

Website

https://delispect.com

Company type

Private

Founded year

2024

Operating status

Operating

Short description

Delispect is a Japanese medical technology startup developing AI-powered medical devices that predict and manage delirium in elderly hospitalized patients, using a proprietary ML model trained on over 100,000 clinical samples alongside a nurse-facing care navigation application.

Ownership category

akta.pro rank

Product category

AI Medical Devices - Clinical Decision Support

NAICS

Information (51)

SIC

Services-Prepackaged Software (7372), Services-Computer Integrated Systems Design (7373)

akta.pro primary industry

Diagnostic & Triage Decision Support (HLACAGAA)

akta.pro secondary industry

Sepsis, Deterioration & Rapid Response CDS (HLACAGAF)

Keywords

• AI medical devices
• Delirium prediction
• Clinical decision support
• Hospital software
• Elderly care AI

Headquarters

HQ city

Tokyo

HQ country

Japan

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations

Revenue model

1. AI Medical Device Software: DELISPECT develops an AI medical device for delirium prediction. As a medical device startup, the primary revenue model likely involves software licensing to hospitals, either as subscription or one-time license, with potential professional services for implementation and training.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Delispect develops AI-powered medical devices for predicting and managing delirium in elderly hospitalized patients. The company offers a proprietary machine learning-based delirium onset prediction model trained on 100,000+ clinical data samples, alongside a care navigation application that standardizes delirium prevention protocols for nurses and caregivers. Both products operate using existing hospital data without requiring invasive sensors.

Product overview

DELISPECT is a medical device startup developing AI-powered solutions for delirium in elderly hospitalized patients. The company offers two integrated products: (1) a delirium onset prediction model using proprietary machine learning trained on over 100,000 clinical data samples, requiring no invasive sensors, and (2) a delirium care navigation application that standardizes prevention care and assists with individualized care plan creation. Both products work together to predict delirium risk and guide healthcare workers through optimal prevention protocols.

Differentiator

Problem solved

Functional benefit

Products and services

• Delirium Onset Prediction Model (せん妄発症予測モデル) AI-powered machine learning model that predicts delirium onset in elderly hospitalized patients using routinely collected hospital patient data. Trained on over 100,000 clinical data samples, offering non-invasive prediction without requiring brain wave sensors or new data collection. Delivered to hospitals as an AI medical device.
• Delirium Care Navigation (せん妄ケアナビゲーション) Navigation application that supports delirium prevention care for nurses and caregivers. Standardizes delirium response that previously depended on nurse experience levels, and assists in creating optimal individualized care plans, supervised by delirium researchers and trained nurses. Targets healthcare workers and caregivers in hospital and clinical settings.

Quantifiable outcome

• 30% incidence rate of delirium in hospitalized patients
• +3 more outcomes

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature2 records

Partnerships

Seven partnerships are on record, tiered minor and core.

• 東京都 / Campus Create - スタートアップ×大学 産学連携促進プログラムminorStrategic or Co-development Partner · 30 May 2025Selected for Tokyo government startup-university collaboration program facilitated by Campus Create.
• 順天堂大学 - JASTARプロジェクトcoreStrategic or Co-development Partner · 26 June 2024Selected for Juntendo University AI Incubation Firm 2nd JASTAR Project - AI startup support program at the university.
• プレモパートナーズ - MedTech Angels 2022minorStrategic or Co-development Partner · 1 January 2022Accepted into medical device-focused acceleration program.
• 国立がん研究センター東病院 (National Cancer Center East Hospital)coreStrategic or Co-development PartnerMultiple ongoing clinical research collaborations on delirium prediction model development. The hospital's Psycho-Oncology Division, led by co-founder Dr. Ogawa, conducts joint research on delirium prediction factors and model validation.
• 順天堂大学医学部付属順天堂医院 (Juntendo University Hospital)coreStrategic or Co-development PartnerClinical research collaboration on delirium prediction model development with one of Japan's leading university hospitals.
• 聖路加国際病院 (St. Luke's International Hospital)coreStrategic or Co-development PartnerClinical research collaboration on delirium prediction model development.
• 熊本赤十字病院 (Kumamoto Red Cross Hospital)coreStrategic or Co-development PartnerClinical research collaboration on delirium prediction model development.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Emerging players

• Lunit: Korean AI medical device company providing deep-learning diagnostic and therapeutic decision-support solutions to hospitals globally. Comparable Asian AI medtech company with similar hospital-targeting model and predictive analytics DNA.
• Owkin: AI company building machine-learning models on clinical data for hospitals and pharma research. Comparable as a clinical-data-trained ML player targeting healthcare decision support, though earlier-stage and research-leaning.
• Medmain: Japanese AI medical-imaging startup applying deep learning to pathology diagnostics. Comparable as a Japan-rooted AI medical device company pursuing hospital sales, though focused on imaging rather than CDS.
• Ceribell: US-based AI medical device company using machine learning on EEG/brain-monitoring data to detect acute neurological events in hospitals. Comparable as an AI-driven acute-deterioration detection device with similar predictive-CDS commercial motion.

Broad incumbents

• Tempus Labs: US-based AI clinical decision support and precision medicine company applying machine learning to clinical and molecular data for hospital and pharma customers. Comparable as a large-scale AI CDS player, though broader in scope and more mature.
• Philips Health Systems: Global medtech incumbent providing patient monitoring, ICU analytics, and clinical decision support tools to hospitals. Comparable as a large established player in hospital deterioration CDS that could either compete with or partner around Delispect's delirium-specific focus.
• M3 (M3 Inc.): Major Japanese healthcare platform operating MR-kun and clinical decision support/AI tools used by Japanese physicians and hospitals. A logical incumbent competitor in Japanese hospital AI/CDS, with much greater commercial reach.

Regional players

• JMDC: Japanese health-data analytics and informatics company serving payers, providers, and pharma with claims and clinical data platforms. Comparable as a Japanese health-data infrastructure peer; could become a partner or competitor depending on whether Delispect's predictive layer is integrated into JMDC's data stack.

Direct peers

• Aillis: Japanese AI medical device startup developing deep-learning-based diagnostic devices (notably for ear/nose/throat). Highly comparable as a Japan-based, AI medical-device startup at a similar stage, with regulatory focus and hospital go-to-market.
• Ubie: Tokyo-based AI health startup building clinical decision support and symptom-checking tools deployed in Japanese hospitals. Most directly comparable to Delispect as a Japanese AI clinical decision support company targeting hospital workflows.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/delispect0912

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Delispect